Point-of-care Diagnostic for Preeclampsia shown Superior to Current Practice

GROTON, Conn., March 21, 2019 /PRNewswire/ -- GestVision, Inc., a privately-held biotechnology company, applauds the diligent work of the clinical researchers who conducted the first prospective clinical study of a rapid CRD urine diagnostic for confirming or ruling out preeclampsia. The researchers ultimately aim to reduce illness and deaths among expecting mothers and their babies through better disease diagnosis. Recently published in Lancet's E-Clinical Medicine (https://doi.org/10.1016/j.eclinm.2019.02.004), the study from The Ohio State University College of Medicine, The Ohio State University Wexner Medical Center, and Nationwide Children's Hospital demonstrated CRD test results strongly correlated with the diagnosis of preeclampsia (PE) rendered by experts.

"The diagnosis of preeclampsia remains challenging," said Kara Rood, MD, Assistant Professor, Maternal Fetal Medicine at Ohio State Wexner Medical Center, and first author on the collaborative project. "What is needed are diagnostic tools designed specifically for determining if a woman with symptoms has preeclampsia, a leading cause of maternal mortality and morbidity."

"This is an important and first US, prospectively- enrolled clinical study of the CRD test in women with signs or symptoms of preeclampsia," said Wendy L. Davis, MBA, Founder and CEO of GestVision. "The finding that the CRD test was superior to other tests used as the standard of care for preeclampsia assessment indicates further development and clinical studies are warranted."

CRD was first developed by Drs. Irina and Catalin Buhimschi (University of Illinois, Chicago) while at Yale University. With a license from Yale, GestVision has developed the GestAssured® test based on similar principals. The Company has initiated a multi-center US clinical study to evaluate the investigational-use-only GestAssured® test.

About GestVision

GestVision, Inc., is a privately-held biotechnology company that is committed to securing safer pregnancies by fearlessly challenging the status quo for women's health. We promise to deliver confidence to healthcare providers to make sound clinical decisions. Our aim is to address the unmet medical needs in women's health by bringing forth premium products based upon robust scientific discoveries. GestVision was founded in 2014 and is headquartered within the BioCT Innovation Commons in Groton, CT. For more information, please visit our website: https://gestvision.com, the content of which is not incorporated herein by reference. Follow us on Twitter @GestVision.

GestVision Media Contact:
Patrice Mason
AXON Communications
+1 914-701-0100 ext. 5354
[email protected]

SOURCE GestVision, Inc.

Related Links

http://www.gestvision.com